文献速递消化内镜消化道肿瘤与早癌

成人嗜酸性食管炎内镜活动评估的差异及内镜评分验证

Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-11-23

研究纳入266例成人嗜酸性食管炎患者评估内镜医师间差异,并开发验证3种基于EREFS的评分系统;发现内镜医师间EndoGA均值差异为2.6±1.8,新评分系统在检测内镜活动变化方面并不优于简单评分系统,支持使用简单评分系统。

要点

  • 内镜医师对嗜酸性食管炎内镜活动的评估存在差异,EndoGA均值差异为2.6±1.8。
  • 新开发的基于回归的评分系统在检测内镜活动变化方面并不优于简单评分系统。
  • 结果支持使用简单评分系统评估嗜酸性食管炎患者的内镜活动。

核心结论

  • 嗜酸性食管炎患者的内镜活动评估在内镜医师间存在差异。
  • 新开发的评分系统在检测内镜活动变化方面并不优于简单评分系统。
  • 这些结果支持使用简单评分系统评估嗜酸性食管炎患者的内镜活动。

研究设计与样本

  • 开发集:5名消化内科医师回顾266例成人嗜酸性食管炎患者的EREFS表现并提供内镜医师整体评估评分(EndoGA,0至10分)。
  • 验证集:收集120例独立成人数据(2013年5月至2014年7月在瑞士和美国中心招募),使用Bland-Altman法评估基于回归系数的评分。
  • 反应性评估:使用一项随机试验数据,患者接受氟替卡松(n=16)或安慰剂(n=8)。

主要发现

  • EndoGA值分布在内镜医师间存在差异(平均ΔEndoGA为2.6±1.8;范围0-6.6)。
  • 内镜特征变异占平均EndoGA变异的90%以上。
  • 验证组中平均EndoGA与基于回归的评分差异较小(范围-4.70至2.03),表明一致性良好。
  • 随机试验中,氟替卡松组简单评分从基线至研究结束降低24.3(安慰剂组降低4.6,P=.052)。
  • 氟替卡松组基于回归的总体评分降低23.5(安慰剂组降低6.56,P=.12),另一评分降低23.8(安慰剂组降低8.44,P=.11)。

临床怎么用

  • 原文结论支持使用简单评分系统评估嗜酸性食管炎患者的内镜活动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is assessed endoscopically (endoscopic activity), based on grades of edema, rings, exudates, furrows, and strictures (EREFS). We examined variations in endoscopic assessments of severity, developed and validated 3 EREFS-based scoring systems, and assessed responsiveness of these systems using data from a randomized placebo-controlled trial of patients with EoE. METHODS: For the development set, 5 gastroenterologists reviewed EREFS findings from 266 adults with EoE and provided endoscopist global assessment scores (EndoGA, scale of 0 to 10); variation (ΔEndoGA) was assessed using linear regression. We evaluated simple scores (features given arbitrary values from 0 to 3) and developed 2 scoring systems (adjusted score range, 0-100). We then fitted our linear regression model with mean EndoGA to data from 146 adults recruited in centers in Switzerland and the United States between April 2011 and December 2012. For the validation set, we collected data from 120 separate adults (recruited in centers in Switzerland and the United States between May 2013 and July 2014), assessing regression coefficient-based scores using Bland-Altman method. We assessed the responsiveness of our scoring systems using data from a randomized trial of patients with EoE given fluticasone (n=16) or placebo (n=8). RESULTS: The distribution of EndoGA values differed among endoscopists (mean ΔEndoGA, 2.6±1.8; range 0-6.6). We developed 2 regression-based scoring systems to assess overall and proximal and distal esophageal findings; variation in endoscopic features accounted for more than 90% of the mean EndoGA variation. In the validation group, differences between mean EndoGA and regression-based scores were small (ranging from -4.70 to 2.03), indicating good agreement. In analyses of data from the randomized trial, the baseline to end of study change in patients given fluticasone was a reduction of 24.3 in simple score (reduction of 4.6 in patients given placebo, P=.052); a reduction of 23.5 in regression-based overall score (reduction of 6.56 in patients given placebo, P=.12), and a reduction of 23.8 (reduction of 8.44 in patients given placebo, P=.11). CONCLUSION: Assessments of endoscopic activity in patients with EoE vary among endoscopists. In an analysis of data from a randomized controlled trial, we found that newly developed scoring systems are no better than simple scoring system in detecting changes in endoscopic activity. These results support the use of a simple scoring system in evaluation of endoscopic activity in patients with EoE. clinicaltrials.gov no: NCT00939263 and NCT01386112.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Schoepfer AM, Hirano I, Coslovsky M, et al. Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2018. PMID: 30476587. doi:10.1016/j.cgh.2018.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。